vs
HELIOS TECHNOLOGIES, INC.（HLIO）与Orthofix Medical Inc.（OFIX）财务数据对比。点击上方公司名可切换其他公司
HELIOS TECHNOLOGIES, INC.的季度营收约是Orthofix Medical Inc.的1.0倍（$220.3M vs $219.9M），HELIOS TECHNOLOGIES, INC.净利率更高（4.7% vs -1.0%，领先5.7%），HELIOS TECHNOLOGIES, INC.同比增速更快（13.3% vs 2.0%），HELIOS TECHNOLOGIES, INC.自由现金流更多（$18.6M vs $16.8M），过去两年Orthofix Medical Inc.的营收复合增速更高（8.0% vs 4.6%）
赫利俄斯科技是一家总部位于美国纽约的上市数据分析企业，在运营末期因收购并运营电影订阅服务MoviePass受到广泛关注，该业务最终导致公司破产。
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
HLIO vs OFIX — 直观对比
营收规模更大
HLIO
是对方的1.0倍
$219.9M
营收增速更快
HLIO
高出11.3%
2.0%
净利率更高
HLIO
高出5.7%
-1.0%
自由现金流更多
HLIO
多$1.8M
$16.8M
两年增速更快
OFIX
近两年复合增速
4.6%
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $220.3M | $219.9M |
| 净利润 | $10.3M | $-2.2M |
| 毛利率 | 33.1% | 71.1% |
| 营业利润率 | 0.6% | 0.2% |
| 净利率 | 4.7% | -1.0% |
| 营收同比 | 13.3% | 2.0% |
| 净利润同比 | -9.6% | 92.4% |
| 每股收益（稀释后） | $0.31 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收HLIOOFIX
| Q4 25 | — | $219.9M | ||
| Q3 25 | $220.3M | $205.6M | ||
| Q2 25 | $212.5M | $203.1M | ||
| Q1 25 | $195.5M | $193.6M | ||
| Q4 24 | $179.5M | $215.7M | ||
| Q3 24 | $194.5M | $196.6M | ||
| Q2 24 | $219.9M | $198.6M | ||
| Q1 24 | $212.0M | $188.6M |
净利润HLIOOFIX
| Q4 25 | — | $-2.2M | ||
| Q3 25 | $10.3M | $-22.8M | ||
| Q2 25 | $11.4M | $-14.1M | ||
| Q1 25 | $7.3M | $-53.1M | ||
| Q4 24 | $4.8M | $-29.1M | ||
| Q3 24 | $11.4M | $-27.4M | ||
| Q2 24 | $13.6M | $-33.4M | ||
| Q1 24 | $9.2M | $-36.0M |
毛利率HLIOOFIX
| Q4 25 | — | 71.1% | ||
| Q3 25 | 33.1% | 72.2% | ||
| Q2 25 | 31.8% | 68.7% | ||
| Q1 25 | 30.6% | 62.8% | ||
| Q4 24 | 30.1% | 69.0% | ||
| Q3 24 | 31.1% | 68.7% | ||
| Q2 24 | 32.1% | 67.8% | ||
| Q1 24 | 31.7% | 67.5% |
营业利润率HLIOOFIX
| Q4 25 | — | 0.2% | ||
| Q3 25 | 0.6% | -8.3% | ||
| Q2 25 | 10.3% | -7.9% | ||
| Q1 25 | 8.7% | -25.2% | ||
| Q4 24 | 7.4% | -5.3% | ||
| Q3 24 | 11.4% | -9.6% | ||
| Q2 24 | 11.8% | -12.5% | ||
| Q1 24 | 9.6% | -15.6% |
净利率HLIOOFIX
| Q4 25 | — | -1.0% | ||
| Q3 25 | 4.7% | -11.1% | ||
| Q2 25 | 5.4% | -6.9% | ||
| Q1 25 | 3.7% | -27.4% | ||
| Q4 24 | 2.7% | -13.5% | ||
| Q3 24 | 5.9% | -13.9% | ||
| Q2 24 | 6.2% | -16.8% | ||
| Q1 24 | 4.3% | -19.1% |
每股收益（稀释后）HLIOOFIX
| Q4 25 | — | $-0.05 | ||
| Q3 25 | $0.31 | $-0.57 | ||
| Q2 25 | $0.34 | $-0.36 | ||
| Q1 25 | $0.22 | $-1.35 | ||
| Q4 24 | $0.14 | $-0.76 | ||
| Q3 24 | $0.34 | $-0.71 | ||
| Q2 24 | $0.41 | $-0.88 | ||
| Q1 24 | $0.28 | $-0.95 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $54.9M | $82.0M |
| 总债务越低越好 | $420.0M | — |
| 股东权益账面价值 | $917.9M | $450.0M |
| 总资产 | $1.6B | $850.6M |
| 负债/权益比越低杠杆越低 | 0.46× | — |
8季度趋势，按日历期对齐
现金及短期投资HLIOOFIX
| Q4 25 | — | $82.0M | ||
| Q3 25 | $54.9M | $62.9M | ||
| Q2 25 | $53.0M | $65.6M | ||
| Q1 25 | $45.9M | $58.0M | ||
| Q4 24 | $44.1M | $83.2M | ||
| Q3 24 | $46.7M | $30.1M | ||
| Q2 24 | $45.0M | $26.4M | ||
| Q1 24 | $37.3M | $27.0M |
总债务HLIOOFIX
| Q4 25 | — | — | ||
| Q3 25 | $420.0M | $157.2M | ||
| Q2 25 | $437.2M | $157.0M | ||
| Q1 25 | $446.7M | $156.9M | ||
| Q4 24 | $450.6M | $157.0M | ||
| Q3 24 | $484.7M | $118.5M | ||
| Q2 24 | $504.0M | $118.0M | ||
| Q1 24 | $521.8M | $118.2M |
股东权益HLIOOFIX
| Q4 25 | — | $450.0M | ||
| Q3 25 | $917.9M | $442.5M | ||
| Q2 25 | $911.7M | $458.3M | ||
| Q1 25 | $881.2M | $458.3M | ||
| Q4 24 | $864.4M | $503.1M | ||
| Q3 24 | $885.5M | $525.9M | ||
| Q2 24 | $866.5M | $546.0M | ||
| Q1 24 | $856.6M | $570.3M |
总资产HLIOOFIX
| Q4 25 | — | $850.6M | ||
| Q3 25 | $1.6B | $832.6M | ||
| Q2 25 | $1.6B | $837.2M | ||
| Q1 25 | $1.5B | $823.1M | ||
| Q4 24 | $1.5B | $893.3M | ||
| Q3 24 | $1.6B | $867.9M | ||
| Q2 24 | $1.6B | $882.0M | ||
| Q1 24 | $1.6B | $906.0M |
负债/权益比HLIOOFIX
| Q4 25 | — | — | ||
| Q3 25 | 0.46× | 0.36× | ||
| Q2 25 | 0.48× | 0.34× | ||
| Q1 25 | 0.51× | 0.34× | ||
| Q4 24 | 0.52× | 0.31× | ||
| Q3 24 | 0.55× | 0.23× | ||
| Q2 24 | 0.58× | 0.22× | ||
| Q1 24 | 0.61× | 0.21× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $25.3M | $27.7M |
| 自由现金流经营现金流 - 资本支出 | $18.6M | $16.8M |
| 自由现金流率自由现金流/营收 | 8.4% | 7.6% |
| 资本支出强度资本支出/营收 | 3.0% | 4.9% |
| 现金转化率经营现金流/净利润 | 2.46× | — |
| 过去12个月自由现金流最近4个季度 | $91.3M | $-1.3M |
8季度趋势，按日历期对齐
经营现金流HLIOOFIX
| Q4 25 | — | $27.7M | ||
| Q3 25 | $25.3M | $12.4M | ||
| Q2 25 | $37.0M | $11.6M | ||
| Q1 25 | $19.0M | $-18.4M | ||
| Q4 24 | $35.7M | $23.7M | ||
| Q3 24 | $34.8M | $11.7M | ||
| Q2 24 | $33.8M | $9.0M | ||
| Q1 24 | $17.8M | $-18.6M |
自由现金流HLIOOFIX
| Q4 25 | — | $16.8M | ||
| Q3 25 | $18.6M | $2.5M | ||
| Q2 25 | $31.6M | $4.5M | ||
| Q1 25 | $12.9M | $-25.1M | ||
| Q4 24 | $28.2M | $15.2M | ||
| Q3 24 | $28.8M | $6.3M | ||
| Q2 24 | $25.8M | $-360.0K | ||
| Q1 24 | $12.3M | $-29.1M |
自由现金流率HLIOOFIX
| Q4 25 | — | 7.6% | ||
| Q3 25 | 8.4% | 1.2% | ||
| Q2 25 | 14.9% | 2.2% | ||
| Q1 25 | 6.6% | -13.0% | ||
| Q4 24 | 15.7% | 7.0% | ||
| Q3 24 | 14.8% | 3.2% | ||
| Q2 24 | 11.7% | -0.2% | ||
| Q1 24 | 5.8% | -15.4% |
资本支出强度HLIOOFIX
| Q4 25 | — | 4.9% | ||
| Q3 25 | 3.0% | 4.8% | ||
| Q2 25 | 2.5% | 3.5% | ||
| Q1 25 | 3.1% | 3.5% | ||
| Q4 24 | 4.2% | 4.0% | ||
| Q3 24 | 3.1% | 2.7% | ||
| Q2 24 | 3.6% | 4.7% | ||
| Q1 24 | 2.6% | 5.6% |
现金转化率HLIOOFIX
| Q4 25 | — | — | ||
| Q3 25 | 2.46× | — | ||
| Q2 25 | 3.25× | — | ||
| Q1 25 | 2.60× | — | ||
| Q4 24 | 7.44× | — | ||
| Q3 24 | 3.05× | — | ||
| Q2 24 | 2.49× | — | ||
| Q1 24 | 1.93× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
HLIO
| Hydraulics | $141.3M | 64% |
| Electronics | $79.0M | 36% |
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
